Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China

PURPOSE: Although immune checkpoint inhibitor monotherapy has been used as a second-line treatment in advanced non-small cell lung cancer (NSCLC), the improvement in progression-free survival (PFS) remains unsatisfactory. We investigated the feasibility of sintilimab plus chemotherapy as a second-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Xiao, Guo, Jun, Tang, Xiaoyong, Zhu, Hui, Zhu, Dongyuan, Zhang, Xiqin, Meng, Xiangjiao, Hua, Ying, Wang, Zhongtang, Zhang, Yan, Huang, Wei, Wang, Linlin, Yuan, Shuanghu, Zhang, Pingliang, Gong, Heyi, Sun, Yulan, Zhang, Yingjie, Liu, Zengjun, Wang, Zhehai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047475/
https://www.ncbi.nlm.nih.gov/pubmed/35482078
http://dx.doi.org/10.1007/s00432-022-04023-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047475/
https://www.ncbi.nlm.nih.gov/pubmed/35482078
http://dx.doi.org/10.1007/s00432-022-04023-z

Ejemplares similares